Users/Patients Information

Wishbone HAE

Please be aware that the content of this page can vary based on the regulatory requirements in your country.

UPDATES REGARDING IMPLANTED DEVICE INFORMATION

Any updated information on implanted devices will be provided to the patients in this section. The Wishbone HAE device will be properly identified with its UDI (Unique Device Identifier).

Please refer to your Implant Card (EU market only), your healthcare centre or doctor to find the UDI corresponding to your device.

IMPLANT CARD (EU MARKET ONLY)

Information present on the implant card (patient name, clinician/hospital name, date of surgery) and on the sticker to affix on the card (device name, serial number, lot number, the UDI, the device model, as well as the names, addresses and the websites of the manufacturer and distributor) shall help to identify the implanted device and report adverse event or incident.

In case of loss or degradation of the implant card, please contact your healthcare center or doctor. Wishbone SA undertakes to supply a new implant card (including the patient label containing the information related to the implanted device) to the healthcare center or doctor. The healthcare center or doctor will fill in the new implant card with the patient’s information as well as with the surgery date and will provide it to the patient.

Contact Wishbone: info@wishbone-biotech.com

PRECAUTIONS FOR PATIENTS

There are no known interactions with specific diagnostic investigations, evaluations, or therapeutic treatments or other procedures such as electromagnetic interference.

Regarding the functional lifetime of the device, no additional follow-up is required. You will be followed by your healthcare center or doctor.

SUMMARY OF SAFETY AND CLINICAL PERFORMANCE FOR PATIENTS (SSCP)

Until EUDAMED is made available, contact Wishbone SA (info@wishbone-biotech.com) for the Summary of Safety and Clinical Performance (SSCP) of the Wishbone HAE device.

COMPOSITION

Wishbone HAE is a xenograft biomaterial composed of hydroxyapatite from bovine origin (80%w/w) and a second phase of synthetic calcium phosphate (20%w/w).

ONLINE INSTRUCTIONS FOR USE (IFU)

Please be aware that the content of the instructions for use can vary based on the regulatory requirements in your country

Wishbone HAE - US marketVersionLink to online IFUMain modifications
US IFUWishbone HAE - IFU US market Rev01Not published because no products on market with this IFU revisionNA
Wishbone HAE - EU marketVersionLink to online IFUMain modifications
EU IFUThe IFU, once approved by the Notified Body, will be posted on Wishbone SA website//
Device P-321 - US marketVersionLink to online IFUMain modifications
US IFUDevice P-321 - IFU US market Rev01Not published because no products on market with this IFU revisionNA

SYMBOLS GLOSSARY